CN

News 2022-03-02

Porton Plans to Invest 420 million to Expand CDMO Production Capacity of Small Molecule API

March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials.



 

This expansion project will add 2 production workshops, utilities workshop, comprehensive warehouses and other facilities, which total construction area is 31,270. With an estimated new production capacity of 300 m3, it is planned to be completed and put into operation by the end of 2023. In the future, Porton will undertake more high value-added intermediates and API production projects, which will help further consolidate the company's comprehensive capabilities as an End-to-End CDMO service platform.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

This website contains information on products which are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your countries. Please be aware that we do not take any responsibity for accessing suchinlomaon which may not compy wih anylegal process,regulaion,registraton or usage in the counry of your origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

Copyright © PORTON 2024. All Rights Reserved.

Legal Notices Porton Privacy
US: (609) 860-1300
CN: (86) 23-8608-3200